Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study)-Reference-Cited by-同舟云学术

Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study)

Published:2012-06-30 Issue:6 Volume:72 Page:851-857
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Ann Rheum Dis

Author:

Leirisalo-Repo Marjatta,Kautiainen Hannu,Laasonen Leena,Korpela Markku,Kauppi Markku J,Kaipiainen-Seppänen Oili,Luosujärvi Riitta,Luukkainen Reijo,Karjalainen Anna,Blåfield Harri,Uutela Toini,Ilva Kirsti,Julkunen Heikki A,Paimela Leena,Puolakka Kari,Moilanen Eeva,Hannonen Pekka J,Möttönen Timo,

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Actualización del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas y sintéticas dirigidas en la artritis reumatoide;Reumatología Clínica;2024-07

2. Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set;Annals of the Rheumatic Diseases;2024-05-22

3. The effect of a tight control regime with monthly follow‐up on remission rates and reported pain in early rheumatoid arthritis;Musculoskeletal Care;2022-08-12

4. Biologic DMARDs and targeted synthetic DMARDs and the risk of all-cause mortality in rheumatoid arthritis: A systematic review and meta-analysis;Medicine;2022-08-12

5. The Risk of Adverse Effects of TNF-α Inhibitors in Patients With Rheumatoid Arthritis: A Network Meta-Analysis;Frontiers in Immunology;2022-02-16